Mesenchimal stem cells: a possible role in the pathogenesis and treatment of spondyloarthritis

Perrotta, Fabio Massimo; Guerra, Germano; Socio, Antonia De; Scriffignano, Silvia; Lubrano, Ennio

doi:10.4081/reumatismo.2017.976

Cited by 2 publications

(1 citation statement)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the last decade, research has increasingly focused on mesenchymal cells (MSCs) as potentially useful tools in medicine. MSCs have manifold activities, including the capacity for migration to injury sites for tissue regeneration, the self-renewal aptitude, and both the high ability for cell differentiation and modulatory regulation of the inflammatory system [1,2,3,4,5].…”

Section: Introductionmentioning

confidence: 99%

FGF23 and Fetuin-A Interaction and Mesenchymal Osteogenic Transformation

Mattinzoli

Ikehata

Tsugawa

et al. 2019

IJMS

View full text Add to dashboard Cite

Recently, we found a strict bone association between Fibroblast growth factor 23 (FGF23) and Fetuin-A, both involved in cardiovascular and mineral bone disorders. In this study, an uninvestigated bone marrow positivity for both was found. Though the role of exogenous FGF23 on mesenchymal cells (MSCs) was reported, no information is as yet available on the possible production of this hormone by MSCs. To further analyze these uninvestigated aspects, we studied human primary cells and mouse and human cell lines by means of immunostaining, qRT-PCR, enzyme linked immunosorbent assays, chromatin immunoprecipitation, transfection, and a streamlined approach for the FGF23–Fetuin-A interaction called Duolink proximity ligation assay. Mesenchymal cells produce but do not secrete FGF23 and its expression increases during osteo-differentiation. Fibroblast growth factor 23 is also involved in the regulation of Fetuin-A by binding directly to the Fetuin-A promoter and then activating its transcription. Both FGF23 overexpression and addition induced an upregulation of Fetuin-A in the absence of osteo-inducer factors. Fibroblast growth factor 23 and Fetuin-A promoter were increased by osteo-inducer factors with this effect being abolished after FGF23 silencing. In conclusion, both FGF23 and Fetuin-A are present and strictly linked to each other in MSCs with FGF23 driving Fetuin-A production. This mechanism suggests a role for these two proteins in the osteoblast differentiation.

show abstract

Section: Introductionmentioning

confidence: 99%

FGF23 and Fetuin-A Interaction and Mesenchymal Osteogenic Transformation

Mattinzoli

Ikehata

Tsugawa

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

Unmet Needs in Axial Spondyloarthritis

Lubrano

Socio

Perrotta

2017

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

During the past decade, the well-known disease called ankylosing spondylitis has come to be considered as a subset of the broader entity referred as axial spondyloarthritis (axSpA), which also includes non-radiographic axSpA. The need of this new classification was aimed to improve the sensitivity for an early diagnosis, to reduce diagnostic delay, and to allow an early treatment. Although there is improvement in the recognition, the management of patients, and the treatment strategies of axSpA, unmet needs persist. There is still a substantial gap of 5-8 years between the onset of symptoms and the diagnosis of axSpA and, even in patients diagnosed early, 20-40% of them do not respond or have a loss of response to anti-TNF treatment. Moreover, the pathogenesis of the disease and, in particular, the mechanisms of new bone formation are far to be completely understood. Nevertheless, the discovery of IL-23/IL-17 axis with the development of biologic inhibitors, the identification of new subsets of effector cells, together with the interest in the detection of potential biomarkers of bone formation brought the approach to axSpA into a new era. This review is intended to enhance awareness and understanding of axSpA and to identify and discuss the current unmet needs in axSpA, including diagnosis, classification, biomarkers, pathogenesis, management, and treatment strategies.

show abstract

Mesenchimal stem cells: a possible role in the pathogenesis and treatment of spondyloarthritis

Cited by 2 publications

References 60 publications

FGF23 and Fetuin-A Interaction and Mesenchymal Osteogenic Transformation

FGF23 and Fetuin-A Interaction and Mesenchymal Osteogenic Transformation

Unmet Needs in Axial Spondyloarthritis

Contact Info

Product

Resources

About